Lightnews — Scholar-powered news

updates.chemo.org.uk @updates.chemo.org.uk · 2d

Isatuximab in combination with bortezomib,...- in combination (with bortezomib, lenalidomide, and dexamethasone) for the treatment of UNTREATED multiple myeloma when a stem c...

https://updates.chemo.org.uk/CDF_Forms/ISA2.html

🚨 Date moving into routine commissioning upd...

1

updates.chemo.org.uk @updates.chemo.org.uk · 2d

Durvalumab- Durvalumab monotherapy for patients with limited- stage small cell lung cancer whose disease has not progressed following plati...

https://updates.chemo.org.uk/CDF_Forms/DUR7.html

🚨 Treatment criterion (#7) and date moving i...

1

updates.chemo.org.uk @updates.chemo.org.uk · 2d

Brigatinib monotherapy- For anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously untreated with an ALK inhibitor

https://updates.chemo.org.uk/CDF_Forms/BRI2.html

🚨 Drug column updated; Treatment criterion (...

1

updates.chemo.org.uk @updates.chemo.org.uk · 2d

Alectinib monotherapy- For anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously untreated with an ALK inhibitor where th...

https://updates.chemo.org.uk/CDF_Forms/ALE1.html

🚨 Drug column updated; Treatment criterion (...

1

updates.chemo.org.uk @updates.chemo.org.uk · 2d

NA- NA

https://updates.chemo.org.uk/CDF_Forms/NHSE Urgent Interim.html

🚨 Removed from CDF weblist

1

updates.chemo.org.uk @updates.chemo.org.uk · 2d

Lorlatinib monotherapy- Lorlatinib monotherapy for anaplastic lymphoma kinase-positive advanced non- small cell lung cancer previously untreated with a...

https://updates.chemo.org.uk/CDF_Forms/LOR2.html

🚨 Recommended for routine commissioning, rec...

1

updates.chemo.org.uk @updates.chemo.org.uk · 2d

🤖 Automated message

NHS England has updated the Cancer Drugs Fund List to version 1.375.

https://updates.chemo.org.uk/news/CDFNews_1.375.html

Changes - 👇 🧵

NHS England updates CDF List – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

1 1

updates.chemo.org.uk @updates.chemo.org.uk · 2d

🤖 Automated message

5 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-10-09.html

Changes: nivolumab, atezolizumab, amivantamab, cytarabine

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · 5d

🤖 Automated message

3 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-10-06.html

Changes: belimumab, nivolumab, tivozanib hydrochloride monohydrate

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · 9d

🤖 Automated message

5 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-10-02.html

Changes: cabozantinib, selpercatinib, belimumab, nivolumab

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · 12d

🤖 Automated message

6 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-09-29.html

Changes: fingolimod hydrochloride, anastrozole, cabozantinib, belimumab

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · 16d

🤖 Automated message

3 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-09-25.html

Changes: hydroxycarbamide, fingolimod hydrochloride, belimumab

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · 19d

🤖 Automated message

5 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-09-22.html

Changes: dabrafenib mesilate, Idecabtagene vicleucel, niraparib tosylate monohydrate, hydroxycarbamide

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · 22d

Enfortumab vedotin in combination with pem...- Enfortumab vedotin with pembrolizumab for untreated, unresectable or metastatic urothelial cancer, when platinum-based chemothe...

https://updates.chemo.org.uk/CDF_Forms/ENF1.html

🚨 Date moving into routine commissioning upd...

updates.chemo.org.uk @updates.chemo.org.uk · 22d

Durvalumab- Durvalumab monotherapy for patients with limited- stage small cell lung cancer whose disease has not progressed following plati...

https://updates.chemo.org.uk/CDF_Forms/DUR7.html

🚨 Recommended for routine commissioning, rec...

1

updates.chemo.org.uk @updates.chemo.org.uk · 22d

🤖 Automated message

NHS England has updated the Cancer Drugs Fund List to version 1.374.

https://updates.chemo.org.uk/news/CDFNews_1.374.html

Changes - 👇 🧵

NHS England updates CDF List – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

1

updates.chemo.org.uk @updates.chemo.org.uk · 23d

🤖 Automated message

7 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-09-18.html

Changes: bleomycin sulfate, belimumab, amivantamab, dabrafenib mesilate, Idecabtagene vicleucel

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · 26d

🤖 Automated message

10 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-09-15.html

Changes: ruxolitinib phosphate, pomalidomide, bleomycin sulfate, amivantamab

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · Sep 11

🤖 Automated message

14 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-09-11.html

Changes: apalutamide, teriflunomide, pemetrexed disodium, Bosutinib, acalabrutinib maleate, cetuximab, ...

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · Sep 8

🤖 Automated message

CRUK/UK SACT Board have updated consent forms.

https://www.cancerresearchuk.org/health-professional/treatment-and-other-post-diagnosis-issues/consent-forms-for-sact-systemic-anti-cancer-therapy

Changes: Supportive medicines - reviewed and updated

Consent forms for SACT (Systemic Anti-Cancer Therapy)

Standardised SACT regimen-specific consent forms for Clinicians and healthcare professionals involved with consenting and treating patients with SACT.

www.cancerresearchuk.org

updates.chemo.org.uk @updates.chemo.org.uk · Sep 8

🤖 Automated message

7 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2025-09-08.html

Changes: axicabtagene ciloleucel, atezolizumab, nivolumab, apalutamide, pemetrexed disodium

Updated Summary of Product Characteristics – Chemotherapy Updates

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

updates.chemo.org.uk

updates.chemo.org.uk @updates.chemo.org.uk · Sep 5

Pembrolizumab in combination with platinum...- Pembrolizumab in combination with platinum-containing chemotherapy (carboplatin and paclitaxel) for the 1st line treatment of m...

https://updates.chemo.org.uk/CDF_Forms/PEMB32.html

🚨 Date moving into routine commissioning upd...

updates.chemo.org.uk @updates.chemo.org.uk · Sep 5

Nivolumab with ipilimumab- Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair def...

https://updates.chemo.org.uk/CDF_Forms/NIV24.html

🚨 Moved into routine commissioning - section...

1

updates.chemo.org.uk @updates.chemo.org.uk · Sep 5

NA- NA

https://updates.chemo.org.uk/CDF_Forms/DOS2.html

🚨 Moved into routine commissioning - section...

1

updates.chemo.org.uk @updates.chemo.org.uk · Sep 5

Capivasertib in combination with fulvestrant- Capivasertib in combination with fulvestrant for hormone receptor-positive, HER2-negative, locally advanced or metastatic breas...

https://updates.chemo.org.uk/CDF_Forms/CAP1.html

🚨 Moved into routine commissioning - section...

1